SCHEMBL18129485

SCHEMBL18129485

NS(=O)(=O)c1cccc(-c2cnc3[nH]cc(C4=CCN(C(=O)NC5CCCC5)CC4)c3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.47
CAMKK2 Q96RR4 2/20 0.44
DYRK1A Q13627 4/20 0.43
CCNT1 O60563 1/20 0.43
CDK9 P50750 1/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
MAP3K11 Q16584 2/20 0.42
CHEK1 O14757 3/20 0.42
CHEK2 O96017 3/20 0.42
CDK1 P06493 3/20 0.42
PIM1 P11309 3/20 0.42
FGFR1 P11362 3/20 0.42
RPS6KB1 P23443 3/20 0.42
CDK2 P24941 3/20 0.42
MARK3 P27448 3/20 0.42
MAPK1 P28482 3/20 0.42
FLT4 P35916 3/20 0.42
FLT3 P36888 3/20 0.42
CLK2 P49760 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18129540 0.92 CAMKK2 (0.53) RIPK1CAMKK2DYRK1ACCNT1CDK9
SCHEMBL18129474 0.91 DYRK1A (0.49) RIPK1CAMKK2DYRK1ACCNT1CDK9
SCHEMBL18129503 0.91 RIPK1 (0.46) RIPK1CAMKK2DYRK1ACCNT1CDK9
SCHEMBL18129564 0.91 RIPK1 (0.46) RIPK1CAMKK2DYRK1ACCNT1CDK9
SCHEMBL18129799 0.88 GAA (0.46) RIPK1CAMKK2DYRK1ACCNT1CDK9
SCHEMBL18129634 0.87 CAMKK2 (0.50) CAMKK2DYRK1AMAP3K11CHEK1CHEK2
SCHEMBL18129717 0.87 CAMKK2 (0.44) RIPK1CAMKK2DYRK1AMAP3K11CHEK1
SCHEMBL18129557 0.86 CAMKK2 (0.45) RIPK1CAMKK2DYRK1AMAP3K11CHEK1
SCHEMBL18129523 0.85 HTR1D (0.48) RIPK1CAMKK2DYRK1ACCNT1CDK9
SCHEMBL18129534 0.85 RIPK1 (0.46) RIPK1CAMKK2DYRK1AMAP3K11CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2019-03-26 US claimed
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-13 US claimed
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2019-03-26 US disclosed
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2019-03-26 US disclosed
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-13 US disclosed
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TANK, NFKBIA, TBK1 RIPK1 96/4885CAMKK2 387/4885DYRK1A 1134/4885
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same NFKBIA, TANK, TBK1 RIPK1 85/4885CAMKK2 366/4885DYRK1A 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.